NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of WPP plc (“WPP” or the “Company”) (NYSE: WPP) between February 27, 2025, to July 8, 2025, inclusive. You are hereby notified that the class action lawsuit Jack Marty v. WPP plc, et al. (Case No. 1:25-cv-08365) has been commenced in the United States District Court for the Southern District of New York. To get more informa ...

NEW YORK CITY and NEW ORLEANS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pe ...

Core Viewpoint - A securities class action lawsuit has been filed against Dow Inc. for failing to disclose material information during the class period, which has led to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who purchased Dow securities between January 30, 2025, and July 23, 2025, have until October 28, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Eastern District of Michigan, under the case name Sarti v. Dow Inc., No. 25-cv-12744 [5]. Group 2: Financial Performance - On July 24, 2025, Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly higher than the expected loss of approximately $0.17 to $0.18 per share [4]. - The company's net sales for the same quarter were $10.1 billion, reflecting a 7.3% year-over-year decline and missing consensus estimates by $130 million [4]. - Dow announced a dividend cut from $0.70 per share to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment [4]. Group 3: Market Reaction - Following the financial disclosures, Dow's share price fell by $5.30, or 17.45%, closing at $25.07 per share on July 24, 2025 [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 14, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar ...

Few events can disrupt a public company’s trajectory as suddenly as the publication of a short-seller report.  Often sensational in tone and light on substance, these reports typically allege that a company has misstated its financial condition, overstated business prospects, or engaged in improper practices.  The motive is rarely hidden: drive the stock price down for the short-seller’s own financial gain.The impact, however, extends far beyond short-term market volatility. In today’s litigation landscape, ...

Core Viewpoint - A securities class action lawsuit has been filed against Fortinet, Inc. due to allegations of misleading statements regarding its product refresh cycle and growth projections [1][6]. Allegations - The lawsuit claims that Fortinet's statements about entering a major firewall "refresh cycle" were false and misleading, as the refresh involved old products that represented only a small part of the business [6]. - Fortinet projected $400 million to $450 million in product revenue for 2025-2026, but the lawsuit argues that the company lacked clarity on the number of firewalls that could actually be upgraded [6]. - By the second quarter of 2025, Fortinet had already completed nearly half of the refresh, contradicting claims of future momentum [6]. Stock Impact - Following the revelation on August 6, 2025, that Fortinet was 40-50% through the 2026 upgrade cycle and that customers had excess firewall capacity, the company's stock fell by 22%, from $96.58 to $75.30 on August 7, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements about the company's performance while concealing material adverse facts about its advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with its ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Next Steps for Investors - Investors who purchased Snap shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (“Cytokinetics” or the “Company”) securities between December 27, 2023, and May 6, 2025 (the “Class Period”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATIO ...

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which could impact the company's regulatory approval timeline [1][8]. Allegations - Defendants are accused of making materially false statements about the expected timeline for the NDA submission and approval process for aficamten, claiming FDA approval was anticipated in the second half of 2025 with a PDUFA date of September 26, 2025 [8]. - The company allegedly failed to disclose significant risks, particularly the omission of a required Risk Evaluation and Mitigation Strategy (REMS), which could lead to delays in regulatory approval [8]. Key Dates - Investors must contact the law firm before November 17, 2025, to be eligible for the lead plaintiff motion deadline [4]. Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, with over 125 years of experience in securities litigation, is representing the investors in this case, emphasizing their commitment to justice for those financially harmed by misrepresented statements [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses exceeding $50,000 in Savara between March 7, 2024, and May 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Savara, with a deadline of November 7, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Savara and its executives made false statements regarding the MOLBREEVI BLA, including insufficient information about its chemistry and manufacturing, which likely affected FDA approval [6]. Group 2: Stock Performance and Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA on May 27, 2025, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share [7]. Group 3: Company Background and Recovery - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995, with offices in multiple states [5]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].